Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jul;271(7):4203-4215.
doi: 10.1007/s00415-024-12338-9. Epub 2024 Apr 10.

Clinical and neuroanatomical characterization of the semantic behavioral variant of frontotemporal dementia in a multicenter Italian cohort

Affiliations
Multicenter Study

Clinical and neuroanatomical characterization of the semantic behavioral variant of frontotemporal dementia in a multicenter Italian cohort

Alma Ghirelli et al. J Neurol. 2024 Jul.

Abstract

Background: Semantic behavioral variant frontotemporal dementia (sbvFTD) is a neurodegenerative condition presenting with specific behavioral and semantic derangements and predominant atrophy of the right anterior temporal lobe (ATL). The objective was to evaluate clinical, neuropsychological, neuroimaging, and genetic features of an Italian sbvFTD cohort, defined according to recently proposed guidelines, compared to semantic variant primary progressive aphasia (svPPA) and behavioral variant FTD (bvFTD) patients.

Methods: Fifteen sbvFTD, sixty-three bvFTD, and twenty-five svPPA patients and forty controls were enrolled. Patients underwent clinical, cognitive evaluations, and brain MRI. Symptoms of bvFTD patients between onset and first visit were retrospectively recorded and classified as early and late. Grey matter atrophy was investigated using voxel-based morphometry.

Results: sbvFTD experienced early criteria-specific symptoms: world, object and person-specific semantic loss (67%), complex compulsions and rigid thought (60%). Sequentially, more behavioral symptoms emerged (apathy/inertia, loss of empathy) along with non-criteria-specific symptoms (anxiety, suspiciousness). sbvFTD showed sparing of attentive/executive functions, especially compared to bvFTD and better language functions compared to svPPA. All sbvFTD patients failed at the famous face recognition test and more than 80% failed in understanding written metaphors and humor. At MRI, sbvFTD had predominant right ATL atrophy, almost specular to svPPA. Three sbvFTD patients presented pathogenic genetic variants.

Conclusion: We replicated the application of sbvFTD diagnostic guidelines in an independent Italian cohort, demonstrating that the presence of person-specific semantic knowledge loss and mental rigidity, along with preserved executive functions and a predominant right ATL atrophy with sparing of frontal lobes, should prompt a diagnosis of sbvFTD.

Keywords: FTD; MRI; Voxel-based morphometry; rtvFTD; sbvFTD.

PubMed Disclaimer

Conflict of interest statement

A. Ghirelli and E.G. Spinelli has nothing to disclose. E. Canu has received research supports from the Italian Ministry of Health. S. Basaia has received research supports from the Italian Ministry of Health. V. Castelnovo, G. Cecchetti, E. Sibilla, T. Domi, G. Magnani, F. Caso, P. Caroppo, S. Prioni, C. Villa, G. Rossi, L. Tremolizzo, I. Apollonio, F. Verde, N. Ticozzi, and V. Silani has nothing to disclose. M. Filippi is Editor-in-Chief of the Journal of Neurology; Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA, participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda, scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. F. Agosta is Associate Editor of NeuroImage: Clinical; has received speaker honoraria from Biogen Idec, Italfarmaco, Roche, Zambon and Eli Lilly; and receives or has received research supports from the Italian Ministry of Health, the Italian Ministry of University and Research, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council, the EU Joint Programme—Neurodegenerative Disease Research (JPND), and Foundation Research on Alzheimer Disease (France).

Figures

Fig. 1
Fig. 1
Sample selection and study design. Two hundred eighty-three patients with a suspected diagnosis of FTLD-spectrum disease were enrolled at San Raffaele Hospital between 2017 and 2023. Of these, 236 were confirmed for an FTLD-related disorder. Fifteen patients (6.4%) had sbvFTD. The remaining patients had bvFTD (n = 63, 26.7%), svPPA (n = 25, 10.5%), nfvPPA (n = 21, 8.4%), MND (n = 67, 28.4%), atypical parkinsonism (n = 45, 19%). For the purposes of this study, we included only patients with a diagnosis of sbvFTD, bvFTD or svPPA, for a total number of 103 subjects. Detected genetic mutations are reported in the last pie chart. bvFTD behavioral variant frontotemporal dementia, C9orf72 chromosome 9 open reading frame 72, FTLD frontotemporal lobar degeneration, FUS fused in sarcoma, GRN progranulin, MAPT microtubule associated protein tau, MND motor neuron disease, sbvFTD semantic behavioral variant frontotemporal dementia, svPPA semantic variant primary progressive aphasia, TREM2 triggering receptor expressed on myeloid cells 2
Fig. 2
Fig. 2
Symptoms developed by semantic behavioral FTD (sbvFTD) patients. Spider chart depicting the number of sbvFTD patients affected by a given symptom. Blue line represents the first three symptoms reported by caregivers/patients; orange line represents all symptoms reported from disease onset to the time of the visit. “Extra-criteria” symptoms = anxiety, suspiciousness, agitation, irritability or depression
Fig. 3
Fig. 3
Patterns of gray matter atrophy in patients with behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia (svPPA), and semantic behavioral frontotemporal dementia (sbvFTD). Results of voxel-based morphometry analysis showing regions of significant GM atrophy in bvFTD patients compared to healthy controls (HC) (A), svPPA compared to HC (B), and sbvFTD compared to HC (C). Composite image showing svPPA and sbvFTD patterns of atrophy, combined with green areas showing regions of overlapping volume loss (D). Significant clusters are overlaid on sections of the Montreal Neurologic Institute standard brain. Analyses were corrected for age, sex, and total intracranial volume. Statistical threshold for significance was p < 0.05, family-wise error corrected for multiple comparisons. bvFTD behavioral variant frontotemporal dementia, sbvFTD semantic behavioral variant frontotemporal dementia, svPPA semantic variant primary progressive aphasia
Fig. 4
Fig. 4
Patterns of gray matter atrophy in patients with semantic behavioral variant frontotemporal dementia (sbvFTD) compared to behavioral variant frontotemporal dementia (bvFTD) and semantic variant primary progressive aphasia (svPPA). Results of voxel-based morphometry showing regions of significant GM atrophy in bvFTD compared to sbvFTD (A), sbvFTD compared to bvFTD (B), svPPA compared to sbvFTD (C), sbvFTD compared to svPPA (D). Significant clusters are overlaid on sections of the Montreal Neurologic Institute standard brain. Analyses were corrected for age, sex, and total intracranial volume. Statistical threshold for significance was p < 0.05, family-wise error corrected for multiple comparisons. For uncorrected results, threshold of significance was p < 0.001. bvFTD behavioral variant frontotemporal dementia, sbvFTD semantic behavioral variant frontotemporal dementia, svPPA semantic variant primary progressive aphasia

Similar articles

Cited by

References

    1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–2477. doi: 10.1093/brain/awr179. - DOI - PMC - PubMed
    1. Rabinovici GD, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):2034–2042. doi: 10.1212/WNL.0b013e31823b9c5e. - DOI - PMC - PubMed
    1. Seeley WW, et al. The natural history of temporal variant frontotemporal dementia. Neurology. 2005;64(8):1384–1390. doi: 10.1212/01.WNL.0000158425.46019.5C. - DOI - PMC - PubMed
    1. Chan D, et al. The clinical profile of right temporal lobe atrophy. Brain. 2009;132(Pt 5):1287–1298. doi: 10.1093/brain/awp037. - DOI - PubMed
    1. Josephs KA, et al. Two distinct subtypes of right temporal variant frontotemporal dementia. Neurology. 2009;73(18):1443–1450. doi: 10.1212/WNL.0b013e3181bf9945. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources